Chimerix
dose intensification expected to enhance duration of therapeutic exposure consecutive day dosing may increase therapeutic response phase trial data suggest a therapeutic and safe exposure possible with twice daily three times weekly dosing incubation time hours | Chimerix
Company
Deck Type
Sector
Industry
Deck date
August 2023
Slide
34 of 43
Similar slides by Chimerix
See diffirences between slides (animation)
Investor Presentation
May 2023
dose intensification expected to enhance therapeutic exposure consecutive day dosing may increase incubation time | Chimerix
Investor Presentation
March 2023
dose intensification expected to enhance therapeutic exposure | Chimerix
Related slides by other companies
Ocuphire Pharma
Results
June 2021
primary of subjects letter gain in photopic at hour | Ocuphire Pharma
AstraZeneca
Investor Event
September 2024
profiles of and demonstrate stability of linker in platform and support dosing | AstraZeneca
Ocuphire Pharma
Results
June 2021
secondary of subjects letter gain in photopic at hour | Ocuphire Pharma
DICE Therapeutics
Investor Presentation
March 2023
progression to phase in psoriasis dice severity pas | DICE Therapeutics
Other recent decks by Chimerix
See all presentations (6 decks)
Investor Presentation
May 2023
Investor Presentation
March 2023
Results
March 2022
Investor Conference
November 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights